FDA extends Capricor's deramiocel decision date to 22 November

The FDA reclassified Capricor's submission as a major amendment after the company added 24-month open-label extension data from the phase 3 HOPE-3 trial. The amendment also asks the agency to review existing and new data for a narrower use: upper-limb impairment in patients older than 9 years, rather than DMD cardiomyopathy. Capricor's shares rose as much as 16% on the morning of 24 August and were worth $7.05 at the time of publication.

Advisers voted against the cardiomyopathy indication

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 9 to 3, with no abstentions, on 29 July 2026 that the evidence did not provide substantial evidence of effectiveness for deramiocel in DMD cardiomyopathy. The vote is nonbinding. Members who voted no cited results that shifted with different imputation strategies and patient inclusions. "We have markedly fragile results that can be changed with different imputation strategies [and] different inclusions of different people," said John Teerlink, a cardiologist on the panel. Janet Turk Wittes, a biostatistician, said the data were "very fragile" and "dependent on one or two people." Some members also questioned whether LVEF, as measured in the trial, is a validated surrogate for clinical benefit, and raised a possible safety signal tied to increases in left ventricular volume.

FDA reviewers wrote in briefing documents released on 27 July that HOPE-3 "did not meet its pre-specified primary and secondary efficacy endpoints," showing no statistically significant difference from placebo at 12 months. The agency said the statistical analysis plan was changed after the randomized portion finished and during the open-label extension, producing at least two versions beyond the original. Capricor chief executive Linda Marbán said results are governed by SAP version 3.0, finalized before unblinding, and that the FDA's post-hoc analyses rely on SAP version 1.1, which she called an unsigned incomplete internal draft.

Capricor's stock fell from a 24 July close of $19.83 to a 27 July open of $5.87, a drop of just over 70%, after the briefing documents were published. It closed at $6.57 on 29 July.

What Capricor presented

Deramiocel is an allogeneic cardiosphere-derived cell therapy given by intravenous infusion. Capricor says it works through immunomodulatory and antifibrotic effects, not by replacing dystrophin. No therapy is approved specifically for DMD-associated cardiomyopathy, which is eventually fatal.

HOPE-3 enrolled 106 participants at 20 US sites. In the prespecified percent-change analysis of the PUL 2.0 upper-limb scale, deramiocel showed a 4.55% improvement versus placebo; an absolute-score sensitivity analysis put the difference at 1.1 points. Craig McDonald, the national principal investigator at UC Davis, said the FDA and investigators in the field have regarded a one-point PUL 2.0 difference as clinically meaningful. The Lancet published the trial results, using Capricor's amended outcome measures, during the advisory meeting; the paper reported a 54% slowing of upper-limb disease progression.

Pooled across HOPE-2 and HOPE-3, the analysis covered 62 deramiocel-treated patients and 64 on placebo with PUL assessments. Nathaniel Hogan, Capricor's lead biostatistician, reported a 1.29-point difference favoring deramiocel at 12 months, with a P value of 0.0087. He said the company ran more than 600 alternative analyses of HOPE-3, and that "the vast majority" showed a treatment benefit at or above one point.

In the 64 of 106 HOPE-3 participants with impaired cardiac function at entry, Capricor reported a 2.8 percentage point treatment effect on LVEF at 12 months. In the pooled analysis, the LVEF difference was 2.2 points in the full population and 3.1 points among patients with cardiomyopathy at baseline. Patients on deramiocel for two years in the open-label extension had a 3.4-point decline in PUL 2.0, against a modeled 5.88-point decline drawn from published natural-history data and prognostic models. That comparison is open-label and against external data, not a randomized control.

How the application got here

The FDA issued a complete response letter for deramiocel in July 2025, saying the data fell short of the statutory requirement for substantial evidence of effectiveness. A scheduled 30 July 2025 advisory committee meeting was canceled in June 2025; Marbán told BioSpace she was blindsided by the decision. Capricor reported topline HOPE-3 results in December 2025, saying the trial met its primary and secondary endpoints. The FDA's reviewers later read the same trial as a failure. The agency accepted the resubmission in March 2026 and set a target action date of 22 August 2026.

That date passed without word. The agency then granted the three-month extension. Marbán said in a statement that the additional open-label data and further analyses "strengthen the evidence supporting a refined proposed indication."

What happens next

The action date is 22 November. Marbán has said Capricor would pursue a heart indication for deramiocel later. The company has said it will halt all other pipeline work until it receives further regulatory clarity on deramiocel. Shareholder Kaos Capital objected to that plan in a 21 August letter, writing that "conviction in a lead program is not a license for a Board to concentrate all of a public company's capital, risk, and future in a single regulatory outcome."